Effect of Fluvoxamine on Interleukin-6 Levels in COVID-19 Patients Hospitalized in ICU: A Randomized Clinical Trial.
COVID-19
CRP
Cytokine
Fluvoxamine
IL-6
Interleukin-6
Journal
Tanaffos
ISSN: 1735-0344
Titre abrégé: Tanaffos
Pays: Iran
ID NLM: 101308232
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
13
04
2021
accepted:
23
12
2021
entrez:
7
3
2023
pubmed:
8
3
2023
medline:
8
3
2023
Statut:
ppublish
Résumé
Reviewing the laboratory studies, we observe some drugs with other specified applications, which cause serious inhibitory immune responses in the body. Selective Serotonin Reuptake Inhibitors (SSRIs) are among these drugs. Therefore, the current research aimed to evaluate the effectiveness of one of the SSRI drugs called fluvoxamine on the cytokine levels in COVID-19 patients. The current research included 80 patients with COVID-19 hospitalized in ICU in Massih Daneshvari Hospital. They were entered into the research by an accessible method of sampling and then divided into two groups randomly. One of the groups underwent the treatment with fluvoxamine as the experimental group and the other group did not receive fluvoxamine as the control group. Interleukin-6 (IL-6) and CRP levels were measured before the onset of fluvoxamine consumption and when discharging from the hospital in all members of the sample group. The current study showed that IL-6 levels increased, while CRP levels decreased in the experimental group significantly (P-value≤ 0.01). After consuming fluvoxamine, IL-6 and CRP levels were higher and lower in the females compared to the males, respectively. Considering the effectiveness of fluvoxamine on IL-6 and CRP in COVID-19 patients, it may ultimately come true to use this drug to improve both psychological and physical conditions simultaneously and leave the COVID-19 pandemic behind with less pathology.
Sections du résumé
Background
UNASSIGNED
Reviewing the laboratory studies, we observe some drugs with other specified applications, which cause serious inhibitory immune responses in the body. Selective Serotonin Reuptake Inhibitors (SSRIs) are among these drugs. Therefore, the current research aimed to evaluate the effectiveness of one of the SSRI drugs called fluvoxamine on the cytokine levels in COVID-19 patients.
Materials and Methods
UNASSIGNED
The current research included 80 patients with COVID-19 hospitalized in ICU in Massih Daneshvari Hospital. They were entered into the research by an accessible method of sampling and then divided into two groups randomly. One of the groups underwent the treatment with fluvoxamine as the experimental group and the other group did not receive fluvoxamine as the control group. Interleukin-6 (IL-6) and CRP levels were measured before the onset of fluvoxamine consumption and when discharging from the hospital in all members of the sample group.
Results
UNASSIGNED
The current study showed that IL-6 levels increased, while CRP levels decreased in the experimental group significantly (P-value≤ 0.01). After consuming fluvoxamine, IL-6 and CRP levels were higher and lower in the females compared to the males, respectively.
Conclusion
UNASSIGNED
Considering the effectiveness of fluvoxamine on IL-6 and CRP in COVID-19 patients, it may ultimately come true to use this drug to improve both psychological and physical conditions simultaneously and leave the COVID-19 pandemic behind with less pathology.
Types de publication
Journal Article
Langues
eng
Pagination
214-220Informations de copyright
Copyright© 2022 National Research Institute of Tuberculosis and Lung Disease.
Références
JAMA. 2020 Dec 8;324(22):2292-2300
pubmed: 33180097
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
Psychosomatics. 2020 Sep-Oct;61(5):411-427
pubmed: 32425246
Med Hypotheses. 2020 Nov;144:110140
pubmed: 32768893
Mol Psychiatry. 2016 Dec;21(12):1696-1709
pubmed: 26903267
Life Sci. 2020 Jun 1;250:117583
pubmed: 32217117
Sci Transl Med. 2019 Feb 6;11(478):
pubmed: 30728287
J Clin Invest. 2020 Jul 1;130(7):3345-3347
pubmed: 32352407
Neuropsychopharmacology. 2011 Nov;36(12):2452-9
pubmed: 21796103
Brain Behav Immun. 2012 Mar;26(3):469-79
pubmed: 22251606
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Neuropsychiatr Dis Treat. 2017 Feb 14;13:437-441
pubmed: 28243095
Med Hypotheses. 2020 Nov;144:109985
pubmed: 32554324
Hum Genomics. 2010 Oct;5(1):30-55
pubmed: 21106488
Front Public Health. 2020 Apr 29;8:152
pubmed: 32411652
Am J Psychiatry. 2016 Feb 1;173(2):174-83
pubmed: 26552940
Adv Biomed Res. 2019 Jan 31;8:5
pubmed: 30820426
Behav Brain Res. 2017 Jan 1;316:189-196
pubmed: 27569183
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152